Givinostat Demonstrates Positive Phase 3 Trial Results

Italfarmaco released positive topline data from their Phase 3 trial in Givinostat, an anti-fibrotic for use in ambulant boys with Duchenne over 6 years old and on a chronic steroid regimen. This new data reinforces a previously observed safety profile for Givinostat and adds to a growing dataset collected over the past few years which shows a good tolerability profile and positive outcomes for the cohort.

Read more in Italfarmaco’s press release: